A structured, medically supervised pathway for treatment-resistant addiction — from Miami to New Zealand and beyond, delivered with continuous monitoring and full transparency.
Ibogaine is a psychoactive compound derived from the Tabernanthe iboga shrub, studied in the context of opioid, alcohol, and stimulant use disorders. It is not a treatment anyone should pursue without rigorous medical screening, cardiac clearance, and informed consent.
Every session is gated by a cardiology protocol: three-readings clearance, on-site defibrillation, and a monitoring app for the recovery window.
Learn moreLegal status changes frequently. Nothing here is legal advice — always confirm the current position in your jurisdiction.
self-reported abstinence at 60 days in supervised cohorts.
Observational cohort literature · outcomes vary by individual
Developed alongside New Zealand's prescription pathway, the ibogaine.nz app streams resting ECG, vitals, and mood data to your care team between visits — extending clinical-grade cardiac oversight into the recovery window, wherever you are in the world.
Explore the monitoring appIbogaine is not appropriate for everyone. Current clinical and observational literature focuses on specific substance-use and trauma-related populations, always within a supervised medical framework.
This is not an exhaustive list. A full medical, psychiatric, and cardiac evaluation is required before any treatment decision. Ibogaine carries serious, including fatal, medical risks.